

NOTE: THE ARTICLE BELOW WAS TRANSLATED USING THE MICROSOFT EDGE BROWSER
SOURCE: <http://www.irobotnews.com/news/articleView.html?idxno=30329>

Excretory care robot company Curaco enters the US market

Signed a sales contract with CLS Consortium in the United States

2022-12-16 13:40PM



Ministry of Economy, Seoul, South Korea

Curaco (CEO Lee Hoon Sang), a company specializing in excretory care robots, announced on the 16th that it has signed a distributorship agreement with the CLS (as of 01/01/2023 it is the COHealth) consortium of the United States for the sale of the excretory care robot 'Curaco Carebidet', paving the way for entering the US market.

The Curaco Carebidet is an 'automatic feces disposal device' for the elderly, seriously ill, and disabled people who have difficulty moving, and it replaces paper diapers or liver urinals to automatically process excretion while lying on the bed. When the patient's feces are detected, it is immediately inhaled, cleaned thoroughly with a bidet, and all processes are automatically carried out until hot air drying.

Last month, the CLS (i.e. COHealth) consortium in the United States purchased the Curaco Carebidet and invited four Curaco professionals for about two weeks to conduct a PoC (Proof of Concept) with actual users in the United States.



The general public or patients who conducted demonstrations at the PoC all positively evaluated the hygiene, odor removal, and maintenance of human dignity of the Curaco Carebidet.

The CLS (i.e. COHealth) consortium consisted of leading buyers, consultants, government and hospitals, nursing homes, home care providers, national after-sales and maintenance companies, doctors, nurses, and caregivers from Washington, Florida, San Francisco, and Nevada.

The CLS (i.e. COHealth) consortium said its data on the size of the U.S. market confirmed the marketability of at least 1,40 units in Phase I and at least 2 million units in Phase II. After the PoC, additional orders have already been placed. It has also established a distribution network and AS network in the United States for mass orders in 200.

The CLS (i.e. COHealth) consortium said that Curaco Carebidet is a "game changer" in the care industry and will exert a game-changing influence in the care market in the future.

Meanwhile, Curaco has supplied excretory care robots for 2007 years since 15 and currently holds 118 domestic and foreign patents, and has obtained the necessary certifications for overseas export, such as USFDA (USA), CE (Europe), PSE (Japan), and ISO (international). It won the Innovation Award at CES 2020.

It is the only overseas product that has passed the Japanese long-term care insurance test standard and is supported by 90% of the public salary, and based on this, it has been exported to 20 countries. In recognition of its innovation, publicity, and marketability, it is registered as an innovative product by the Public Procurement Agency, and veterinary contracts can be made with the public sector regardless of the amount.

Curaco is transforming from a manufacturing-based company into a platform company that includes not only services but also patient excretion data by utilizing its block chain patents and AI (artificial intelligence) patent technologies.

Reporter: Park Kyung-il | robot@irobotnews.com | www.irobotnews.com